Treatments
ADVERSE EFFECTS
The patients were randomly grouped to receive either the ICd or Id regimen during the induction stage. Because the patients were old and frail, dexamethasone and cyclophosphamide were administered with reduced doses. The dosage of ixazomib was adjusted to 3 mg for elderly patients with worse comorbidities and more adverse effects to the drug to select an appropriate dose. Detailed regimens were as follows: patients in the ICd group received 4 or 3 mg ixazomib (on the 1st, 8th and 15th days), 10 mg dexamethasone (on the 1st, 2nd, 8th, 9th, 15th, 16th, 22nd, and 23rd days), and 200 mg/m